Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price & Analysis

Corbus Pharmaceuticals Holdings, Inc. (CRBP) rose 1.85% to USD 7.7 as of June 10, 2026 at 08:44 UTC, according to Nexqual real-time market data.

CRBP last closed at USD 7.56; the session ranged USD 7.45–7.94 on volume of 292,334 shares. Market capitalization is $142.66M, with a 52-week range of USD 6.72–20.56 (NCM). Source: Nexqual, June 10, 2026 at 08:44 UTC.

Key Statistics (as of June 10, 2026 at 08:44 UTC)

Technical Analysis (CRBP)

Nexqual's technical model rates CRBP "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:44 UTC.

Analyst Ratings (CRBP)

Wall Street analysts rate CRBP "Strong Buy" based on 10 analysts, with a mean price target of USD 36.5 (range USD 17–54), per Nexqual as of June 10, 2026 at 08:44 UTC.

Earnings (CRBP)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 08:44 UTC.

Financials & Fundamentals (CRBP)

Source: Nexqual, June 10, 2026 at 08:44 UTC.

Financial Health Score (CRBP)

Nexqual rates Corbus Pharmaceuticals Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 08:44 UTC.

Ownership (CRBP)

Source: Nexqual, June 10, 2026 at 08:44 UTC.

Leadership (CRBP)

Corbus Pharmaceuticals Holdings, Inc. is led by Yuval Cohen (age 50), CEO & Director, per Nexqual as of June 10, 2026 at 08:44 UTC.

Major Backers & Investors (CRBP)

Notable institutional backers of Corbus Pharmaceuticals Holdings, Inc. include Cormorant Asset Management, LP, Orbimed Advisors LLC., Aberdeen Group plc, according to Nexqual as of June 10, 2026 at 08:44 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 08:44 UTC.

From Corbus Pharmaceuticals Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)

Key Strengths & Strategy (as disclosed to the SEC)

• Pursuant to the CSPC License Agreement, we received an exclusive license to CRB-701 for the prevention and treatment of all oncology indications in the U.S., Canada, the European Union (including the European Free Trade Area), the U.K, and Australia.
• For example, aspects of our proprietary technology platform are based on unpatented trade secrets and know-how related to the manufacturing of our product candidates.
• We seek to protect our proprietary technology and processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners.
• Development of Drugs in the U.S.   FDA Approval Process   In the U.S., the FDA regulates drugs and biological products under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Service Act, or PHSA, and implementing regulations.

Partnerships

• Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.   Special Protocol Assessment The Federal Food, Drug, and Cosmetic Act directs the FDA to meet with sponsors, pursuant to a sponsor's written request, for the purpose of reaching agreement on the design and size of clinical trials intended to form the primary basis of an efficacy claim in a marketing application.
• We have a clinical supply agreement with CSPC to supply drug substance and drug product in support of clinical activities and we will seek to negotiate a commercial supply agreement with CSPC prior to a marketing application.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:44 UTC. This page is informational and not investment advice.